Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Capital Markets

Samsung Biologics   / Equity Capital Markets

This Insight finalizes our view of the listing of Samsung BioLogics (SB) using information presented at the company’s roadshow meeting and included in the prospectus. We continue to think that the proposed valuation of US$7 billion is too high based on the risks inherent in management’s long-term forecasts. The company should play a significant role in the growth of biologics globally, and is worth monitoring for opportunities post-listing. We think that a lower valuation of no more than US$5 billion would be interesting.

This Insight finalizes our view of the listing of Samsung BioLogics (SB) using information presented at the company’s roadshow meeting and included in the prospectus. We continue to think that the proposed valuation of US$7 billion is too high based on the risks inherent in management’s long-term forecasts. The company should play a significant role in the growth of biologics globally, and is worth monitoring for opportunities post-listing. We think that a lower valuation of no more than US$5 billion would be interesting.

Bespoke Research on China and neighbouring regions, Bixmoor

Bixmoor

Bespoke Research on China and neighbouring regions

Bixmoor specialises in providing bespoke research to business, governments and the financial community on China and neighbouring regions. We seek to build long-term relationships with our clients, based on our expertise, our reliability and our determination to find the right solution.

Thematic (Sector/Industry)

A comprehensive world survey of population heights over the last century has thrown up some surprising results. Americans have had the smallest height gain of any developed country, whereas Koreans have grown by an average of six inches over the last 100 years.

A comprehensive world survey of population heights over the last century has thrown up some surprising results. Americans have had the smallest height gain of any developed country, whereas Koreans have grown by an average of six inches over the last 100 years. 

Global Asset Allocation, Politics & Governance, Ecstrat

John-Paul Smith

Global Asset Allocation, Politics & Governance

Ecstrat

Ecstrat is a consultancy advising on asset allocation between global equity markets, with a focus on the intersection of governments, geopolitics, governance and markets.
 
Over the past few years and more especially since the Great Financial Crisis (GFC), investors have become more focused on short-term market movements and real-time returns and have consequently neglected the analysis of the underlying structural themes that underpin longer term performance.
​
More specifically we believe that the evolution of governance-based relationships between investors, controlling shareholders, labour and the state is one of the primary determinants of both relative and absolute performance between individual equity markets.
 
We will endeavour to provide investors with some of the context surrounding governance-related issues which encompass many different disciplines including history, economics and political science, as well as the financial metrics which are the most obvious manifestation of the structural characteristics of each market.
 
We will pay particular attention to the shifts and potential inflection points for governance in individual markets as these are often the best lead indicators for both economic and market performance.

Cross Asset Strategy

In this brief piece we take a considered stance on the likelihood of Brexit actually proceeding in the wake of June’s referendum and examine some of the strategic implications for equity investors in terms of the potential shifts in sovereign and corporate governance.

In this brief piece we take a considered stance on the likelihood of Brexit actually proceeding in the wake of June’s referendum and examine some of the strategic implications for equity investors in terms of the potential shifts in sovereign and corporate governance.

EM PM, Ecstrat

Emad Mostaque

EM PM

In my last piece I discussed why I thought an actual Brexit was unlikely despite the result of the referendum last week. This piece answers some questions on some of the detail of the likely path ahead and some of the interesting elements around this.

In my last piece I discussed why I thought an actual Brexit was unlikely despite the result of the referendum last week. This piece answers some questions on some of the detail of the likely path ahead and some of the interesting elements around this.

The last few days have seen a maelstrom of opinions and recrimination after the shock referendum decision to leave the EU.The lack of a concrete plan of action for an exit has shocked markets, leaving even those who avoid politics worried about the future.However, looking at the structure of western democracy a departure from the EU is very unlikely.

The last few days have seen a maelstrom of opinions and recrimination after the shock referendum decision to leave the EU.The lack of a concrete plan of action for an exit has shocked markets, leaving even those who avoid politics worried about the future.However, looking at the structure of western democracy a departure from the EU is very unlikely.

United Kingdom

AstraZeneca PLC operates as a holding company. The Company, through its subsidiaries, researches, manufactures, and sells pharmaceutical and medical products. AstraZeneca focuses its operations on eight therapeutic areas, including gastrointestinal, oncology, cardiovascular, respiratory, central nervous system, pain control, anaesthesia, and infection.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

AstraZeneca (AZN SS)

Pass on the Deal, Put on the Watchlist

This Insight finalizes our view of the listing of Samsung BioLogics (SB) using information presented at the company’s roadshow meeting and included...

Kemp Dolliver, CFA

A 'heads Up' on Changing World Heights

A comprehensive world survey of population heights over the last century has thrown up some surprising results. Americans have had the smallest...

Bixmoor

Brexit; Unintended Consequences

In this brief piece we take a considered stance on the likelihood of Brexit actually proceeding in the wake of June’s referendum and examine some...

John-Paul Smith

The Path to No Brexit

In my last piece I discussed why I thought an actual Brexit was unlikely despite the result of the referendum last week. This piece answers some...

Emad Mostaque

Why Brexit (Probably) Won't Happen

The last few days have seen a maelstrom of opinions and recrimination after the shock referendum decision to leave the EU.The lack of a concrete...

Emad Mostaque

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)